2+ hour, 22+ min ago  (319+ words) RQ Bio's lead asset, RQB01, is currently in IND-enabling studies. UK-based RQ Bio has closed a "85. 5m ($115m) Series A funding round to advance its long-acting antibody therapeutic programme RQB01, which targets influenza prevention in high-risk and immunocompromised groups. Frazier Life Sciences led the…...

4+ hour, 59+ min ago  (249+ words) Investors at BIO 2026 say lost life sciences investment has left the US vulnerable while China fosters future big pharma competitors. Funding cuts at US federal agencies have compounded threats to the US's predominance in global biopharma as an ascendant Chinese…...

21+ hour, 49+ min ago  (375+ words) Just a year after spinning out from Scorpion Therapeutics, Antares Therapeutics has secured a big pharma partner to help advance its pipeline of undruggable oncology targeting therapies. Novartis has outlaid up to $1. 9bn to collaborate with Antares Therapeutics, with the two…...

1+ day, 27+ min ago  (549+ words) This partnership marks another addition to the growing list of high-profile collaborations between the consumer health and life science sectors. "URA has banded together with Eli Lilly's direct-to-consumer (DTC) telehealth platform, Lilly Direct, to marry behavioural and pharmaceutical approaches to…...

2+ day, 1+ hour ago  (342+ words) US manufacturers defy the tragedy of the commons by jointly sponsoring efforts to attract new talent amid onshoring. US-based drugmakers are meeting rising demand not by competing for local talent, but by collaborating through trade associations to support the next…...

6+ day, 2+ hour ago  (294+ words) Biogen has entered a definitive agreement to acquire Ray Thera, a biotechnology company specialising in small-molecule therapies for immunology, for up to $1bn. The deal value comprises an upfront payment and further payments tied to the achievement of future clinical and…...

6+ day, 47+ min ago  (394+ words) Global Data says that the industry has "absorbed significant disruption, with high M&A levels testament to recovery. Biopharma executives" confidence in the industry has reached its highest point in four years, reflecting a successful navigation through a largely disrupted…...

6+ day, 1+ hour ago  (257+ words) This joint effort aims to create immunotherapies to selectively trigger immune responses in the tumour microenvironment while limiting effects on healthy tissues. TCEs have shown potential in treating various cancers, but the widespread activation of immune responses carries a risk…...

6+ day, 2+ hour ago  (911+ words) RLTs were a hot topic at ASCO 2026, but experts note that certain limitations must be addressed to facilitate their widespread use in cancer care. Upon its rise to notoriety spearheaded by drugs like Novartis" Pluvicto (lutetium Lu 177 vipivotide tetraxetan), the…...

6+ day, 17+ hour ago  (475+ words) Amidst regulatory turmoil and a funding resurgence, companies provide insights on how they are navigating the changing industry. Following an influx of capital in the early COVID-19 pandemic, the biotech sector entered a sustained investment slump. Now the industry finally…...